The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.226%)
Open: 15.75
High: 15.75
Low: 15.75
Prev. Close: 15.75
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EARNINGS SUMMARY: Novacyt Profit Leaps On Covid-19 Test Kit Demand

Thu, 17th Sep 2020 15:39

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Novacyt SA - Surrey-based biotechnology company making Covid-19 test kits - Revenue for six months to June 30 rockets to EUR72.4 million from EUR7.2 million, with Primerdesign revenue multiplying to EUR70.6 million from EUR3.3 million due to the success of the Covid-19 product portfolio. Margins increase to 83% from 63%. Swings to pretax profit of EUR46.1 million from a EUR1.2 million loss due to revenue surge. First half earnings before interest, tax, depreciation and amortisation surge to EUR49.4 million from EUR153,000. Revenue for the second half to be greater than the first half of the year and margins to be at least at a similar level. Full year revenue expected to exceed EUR150 million and Ebitda to exceed EUR100 million. Cash at June 30 of EUR19.7 million after paying down all long-term debt and significant working capital investment made into stock to ensure the continuity of supply to meet the demand for Covid-19 tests. Shares up 5.0% at 388.50 pence.

----------

ThinkSmart Ltd - Australian digital payments platform business - Pretax profit for year ended June 30 multiplies to GBP53.1 million from GBP524,000, driven by GBP53.7 million fair value gain on revaluation of the retained shareholding in Clearpay Finance Ltd. Revenue falls year-on-year to GBP6.1 million from GBP7.2 million. Continues to manage the wind down of legacy business. Cash and cash equivalents of GBP8.8 million at June 30. Shares up 17% at 44.00 pence.

----------

Supermarket Income REIT PLC - UK-focused supermarket income trust - To raise GBP150 million by way of a placing and subscription of shares at 104 pence each, a 6.3% discount to Wednesday's closing stock price of 111p. Current stock price 109.00p, down 1.8%. Proceeds to fund investment opportunities which are currently in excess of GBP400 million. EPRA net asset value per share for the 12 months to June 30 rises 4% to 101p. Passing rent up 49% at GBP28.7 million. 100% of all rents collected in full. Annual dividend up 3.8% at 5.8p. Increases dividend target for financial 2021 to 5.86p.

----------

Aberdeen Smaller Companies Income Trust PLC - investment trust focused on smaller UK companies - Net asset value total return for six months to June 30 minus 16.9% versus minus 25.0% return from Numis Small Companies excluding Investment Trust index. Net asset value per share 306.14p at June 30, down 18% from 373.86p at December 31. Attributes negative return to Covid-19 pandemic. Stock down 0.8% at 262.00 pence.

----------

DX Group PLC - Slough-based courier and logistics services - Revenue for year ended June 27 rises 2.1% to GBP329.3 million from GBP322.5 million. Pretax loss narrows to GBP1.3 million from GBP1.7 million. Revenue fell by a third immediately post-lockdown, but volumes steadily recovered from April and are now above levels anticipated pre-lockdown. Trading in the first months of financial 2020 ahead of the same period last year. Healthy pipeline of new business opportunities. Sees opportunity to increase volumes and further expand margins. Net cash of GBP12.3 million at June 27, better than expected. Shares down 11% at 17.15 pence.

----------

Destiny Pharma PLC - Brighton-based biotechnology company - Pretax loss for the six months to June 30 widens year-on-year to GBP2.9 million from GBP2.4 million. No revenue generated as the company is still in clinical stage of developing products. Research and development costs rise to GBP2.3 million from GBP1.7 million. Funded through fourth-quarter of 2021. Strong cash position with cash and term deposits of GBP5.6 million at June 30. Stock up 3.5% at 60.00 pence.

----------

GCP Student Living PLC - UK-focused student accommodation provider - EPRA net asset value per share for year to June 30 171.78 pence, up from 165.52p a year ago. Property portfolio value rises to GBP1.00 billion from GBP921.6 million. Student rental growth 4.4% versus 3.5%. Rental income rises year-on-year to GBP47.8 million from GBP44.4 million. Chair Robert Peto to retire at 2020 annual general meeting. Annual dividend unchanged at 6.15p. Shares up 2.2% at 139.00p.

----------

Enwell Energy PLC - Ukraine-focused oil and gas explorer - Revenue for six months to June 30 falls 21% year-on-year to USD24.7 million as a result of weakened gas prices in the period. Pretax profit falls 80% to USD2.6 million from USD13.3 million. Average daily production from the MEX-GOL, SV and VAS fields of 4,545 barrels of oil equivalent per day, down 8% from 4,192 barrels. Cash and cash equivalents of USD54.2 million at June 30 and USD55.5 million at September 13. Shares down 2.5% at 15.13 pence.

----------

Gresham House PLC - London-based asset manager - Assets under management rises 17% in the six months to June 30 to GBP3.26 billion from GBP2.80 billion at December 31, helped by 10% organic growth. Core income up 33% to GBP17.8 million. Pretax loss widens year-on-year to GBP1.6 million from GBP801,000. Well placed for the second half of 2020 and beyond. Strong balance sheet with cash and liquid assets at GBP45.1 million and zero debt. Shares up 5.0% at 724.80 pence.

----------

Regional REIT Ltd - UK-focused real estate investment trust - EPRA net asset value per share falls to 102.6 pence at June 30 from 112.7p at December 31. Resilient rental and property income in six months to June-end of GBP29.4 million versus GBP29.9 million. Rent collection strong with 97.6% of the rent invoiced for the period to June 30 being collected as at September 11. EPRA occupancy rate stable at 89.0%. Cuts first half dividend to 3.4p from 3.8p. Targeting an expected full year dividend of 6.4p. Cash and cash equivalent GBP67.9 million. Shares up 2.8% at 68.89p.

----------

Zephyr Energy PLC - technology-led oil and gas exploration company focused on US - Swings to a pretax profit of USD906,000 for the six months to June 30 from USD826,000 loss due to foreign exchange gains of USD1.6 million versus USD126,000 loss. No revenue generated in either financial periods. Administrative costs fall year-on-year to USD613,000 from USD806,000. Shares down 2.6% at 0.76 pence.

----------

Wilmington PLC - London-based data and information services company - Results for 12 months to June 30 at the top end of range previously provided for both revenue and profit. Revenue for the year down 8% to GBP113.1 million, hurt by no face-to-face events or training in final quarter. Pretax profit down 56% at GBP6.4 million due to Covid-19 impact and absence of disposal gains. Net debt improves to GBP27.7 million at June 30 from GBP33.9 million a year ago. Dividend suspended but remains committed to a resumption of dividends as soon as the trading environment normalises. Profitable in the first two months of financial 2021. Shares down 0.4% at 130.00 pence.

----------

Velocys PLC - Oxford, England-based fuels technology company - Revenue multiplies to GBP180,000 for six months ended June 30 from GBP22,000 a year ago. Pretax loss narrows to GBP2.7 million from GBP4.7 million. Sees significant uplift in demand for sustainable fuels. Cash at period end of GBP816,000 versus GBP4.8 million at December 31. Shares up 2.8% at 6.80p.

----------

SolGold PLC - Australian gold and copper mining company - Pretax loss for the year to June 30 narrows year-on-year to USD13.0 million from USD32.7 million due to a sharp drop in share based payment expenses to USD1.2 million from USD23.9 million. No revenue generated in either financial period. Administrative expenses rise to USD12.4 million from USD9.2 million. Shares down 1.5% at 26.99 pence.

----------

DP Aircraft I Ltd - Guernsey-based aircraft leasing company - Net asset value per share plummets to USD0.6502 for the six months to June 30 from USD1.0304 at December 31. Lease rental income for the first half falls to USD24.4 million from USD28.6 million. Swings to pretax loss of USD72 million from USD11.7 million. Books USD71.2 million impairment against aircraft assets and USD15.7 million against the lease premium, in light of Covid-19 pandemic. Prioritising the preservation of long-term financial stability. Available cash projected at the end of September of USD3 million. Stock up 0.1% at USD0.090.

----------

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
29 Jun 2023 18:55

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more
26 May 2023 10:51

Polarean shares down despite narrowed annual loss and optimism

(Alliance News) - Polarean Imaging PLC shares were down on Friday despite slimming its annual loss, as the company said it now will focus on gaining commercial traction and exploring further financing for its newly US Food & Drug Administration-approved Xenoview device.

Read more
25 May 2023 10:42

IN BRIEF: Destiny Pharma picks interim CEO as Clark makes quick exit

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately "to pursue new challenges". Clark will "support [Destiny] for a limited period to ensure an orderly handover." Non-Executive Director Debra Barker will serve as interim CEO until Destiny appoints a permanent replacement. Barker has held "key roles" at Novartis AG and Polyphor AG, now named Spexis AG. She also has previously worked at Roche Holding AG, Polyneuron Pharmaceuticals AG and GSK PLC.

Read more
18 May 2023 15:03

UK shareholder meetings calendar - next 7 days

Friday 19 May 
Bank of Georgia Group PLCAGM
Permanent TSB Group Holdings PLCAGM
Sancus Lending Group LtdAGM
Monday 22 May 
Blackrock Latin American Investment Trust PLCAGM
Crossword Cybersecurity PLCAGM
Judges Scientific PLCAGM
Stelrad Group PLCAGM
Venture Life Group PLCAGM
Tuesday 23 May 
888 Holdings PLCAGM
Access Intelligence PLCAGM
Arix Bioscience PLCAGM
Bank of Ireland Group PLCAGM
Big Technologies PLCAGM
Bigblu Broadband PLCAGM
Centamin PLCAGM
CT Private Equity Trust PLCAGM
Empresaria Group PLCAGM
Epwin Group PLCAGM
Forterra PLCAGM
Fresnillo PLCAGM
Fulcrum Utility Services LtdGM re issue of conversion shares
Gresham Technologies PLCAGM
Harworth Group PLCAGM
Hilton Food Group PLCAGM
hVIVO PLCAGM
HydrogenOne Capital Growth PLCAGM
IQ-AI LtdAGM
JTC PLCAGM
K3 Business Technology Group PLCAGM
Pebble Group PLCAGM
Portmeirion Group PLCAGM
PPHE Hotel Group LtdAGM
Restaurant Group PLCAGM
Shell PLCAGM
Sherborne Investors (Guernsey) C LtdAGM
TMT Investments PLCAGM
Triple Point Income VCT PLCAGM
Triple Point Social Housing REIT PLCAGM
Trustpilot Group PLCAGM
Twentyfour Income Fund LtdAGM
Wickes Group PLCAGM
Xeros Technology Group PLCAGM
Wednesday 24 May 
4imprint Group PLCAGM
Adriatic Metals PLCAGM
Arbuthnot Banking Group PLCAGM
Artisanal Spirits Co PLCAGM
Bango PLCAGM
Coca-Cola Europacific Partners PLCAGM
Deliveroo PLCAGM
Deltic Energy PLCAGM
Distribution Finance Capital Holdings PLCAGM
Dunedin Enterprise Investment Trust PLCAGM
ECSC Group PLCCourt and General Meetings re Daisy Corporate Services Trading Ltd takeover
Empiric Student Property PLCAGM
Fidelity Japan Trust PLCAGM
HICL Infrastructure PLCAGM
Horizonte Minerals PLCAGM
Intertek Group PLCAGM
Ithaca Energy PLCAGM
Kelso Group Holdings PLCAGM
Lookers PLCAGM
M&G PLCAGM
Mercantile Investment Trust PLCAGM
Microlise Group PLCAGM
Mortgage Advice Bureau Holdings PLCAGM
National World PLCAGM
Ondine Biomedical IncAGM
Petershill Partners PLCAGM
Playtech PLCAGM
Quarto Group IncAGM
Real Estate Investors PLCAGM
Tullow Oil PLCAGM
US Solar Fund PLCAGM
Zotefoams PLCAGM
Thursday 25 May 
Alliance Pharma PLCAGM
Biome Technologies PLCAGM
Capital & Regional PLCAGM
Destiny Pharma PLCAGM
Ferrexpo PLCAGM
Fevertree Drinks PLCAGM
Headlam Group PLCAGM
Henry Boot PLCAGM
Hill & Smith PLCAGM
LBG Media PLCAGM
Life Science REIT PLCAGM
LSL Property Services PLCAGM
NAHL Group PLCAGM
Petrofac LtdAGM
Pharos Energy PLCAGM
Prudential PLCAGM
Regional REIT LtdAGM
Resolute Mining LtdAGM
RM PLCAGM
S&U PLCAGM
Sabre Insurance Group PLCAGM
Schroder Asian Total Return Investment Co PLCAGM
TBC Bank Group PLCAGM
Vanquis Banking Group PLCAGM
Zinc Media Group PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
2 May 2023 19:22

TRADING UPDATES: Macfarlane buys A&G Holdings for GBP3.6 million

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Apr 2023 14:16

Destiny Pharma loss widens as it extends cash runway

(Sharecast News) - Biotechnology company Destiny Pharma reported a loss before tax of £7.7m in its 2022 results on Thursday, widening from £6.3m in the prior year.

Read more
13 Apr 2023 13:59

IN BRIEF: Destiny Pharma annual loss widens as expenses grow

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Pretax loss widens to GBP7.7 million for 2022 from GBP6.3 million in 2021. Administrative expenses increase to GBP7.4 million from GBP6.0 million a year earlier. Research & development expenditure amounts to GBP4.9 million, up from GBP3.7 million in 2021. Looking ahead, Destiny Pharma says it will focus on completing the manufacturing scale-up to deliver clinical trial material for the NTCD-M3 clinical programme being run by our partner Sebela. Chief Executive Officer Neil Clark says: "Destiny Pharma has made good progress in 2022 and in the first quarter of 2023."

Read more
6 Apr 2023 15:42

UK earnings, trading statements calendar - next 7 days

Friday 7 April 
no events scheduled 
Monday 10 April 
no events scheduled 
Tuesday 11 April 
Devolver Digital IncFull Year Results
JTC PLCFull Year Results
Wednesday 12 April 
Argentex Group PLCQ3 Results
DP Eurasia NVFull Year Results
Everyman Media Group PLCFull Year Results
LBG Media PLCFull Year Results
Tharisa PLCTrading Statement
Thursday 13 April 
Brooks Macdonald Group PLCTrading Statement
Churchill China PLCFull Year Results
Destiny Pharma PLCFull Year Results
discoverIE Group PLCTrading Statement
Foresight Group Holdings LtdTrading Statement
Imperial Brands PLCTrading Statement
LSL Property Services PLCFull Year Results
Norcros PLCTrading Statement
PZ Cussons PLCTrading Statement
Tesco PLCFull Year Results
XP Power LtdTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
4 Apr 2023 11:33

Destiny Pharma upbeat on infection prevention study

(Sharecast News) - Destiny Pharma said in an update on Tuesday that its novel medicine for preventing life-threatening infections, 'NTCD-M3', had been shown to colonise the gut successfully in a C difficile infection (CDI) model study after the administration of fidaxomicin.

Read more
24 Mar 2023 15:34

Destiny publishes 'important' research on its preoperative treatment candidate

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the publication of landmark clinical data for 'XF-73' on Friday, in the US-based peer-reviewed journal Infection Control & Hospital Epidemiology.

Read more
16 Mar 2023 06:54

IN BRIEF: Destiny Pharma raises GBP7.3 million total in equity raise

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Gets 33% take-up of open offer of shares, raising GBP340,000. Destiny raises GBP7.3 million gross in total from the open offer, plus a share placing and subscription, all at 35 pence per share. Net proceeds are GBP6.7 million, which will be used to support a collaboration agreement in the US with Sebela Pharmaceuticals for NTCD-M3, Destiny's lead asset for the prevention of clostridioides difficile infection recurrence.

Read more
24 Feb 2023 14:28

Destiny shares fall on fundraise discount despite USD570 million deal

(Alliance News) - Destiny Pharma PLC on Friday said that it has signed a collaboration agreement with Sebela Pharmaceuticals for NTCD-M3, its lead asset for the prevention of clostridioides difficile infection recurrence.

Read more
25 Jan 2023 20:03

TRADING UPDATES: Appreciate gets court date; Corcel completes sale

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
22 Dec 2022 14:06

Destiny Pharma jumps on 2022 progress

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its progress in 2022 on Thursday, including working to finalise a partnering agreement for 'NTCD-M3', which it described as its "most advanced" clinical programme, targeted at infection prevention.

Read more
22 Dec 2022 12:10

LONDON MARKET MIDDAY: UK stocks rise as Paris and Frankfurt head lower

(Alliance News) - Stock prices in London were higher at midday on Thursday, ahead of some key US economic data, while equities elsewhere were less buoyant.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.